Rezolute (RZLT) Return on Capital Employed (2013 - 2026)
Rezolute (RZLT) posted Return on Capital Employed of 70.17% for Q1 2026, down 8.57% sequentially from 64.63% in Q4 2025, and up 1289.0% YoY from 5.05% in Q1 2025.
Rezolute (RZLT) Return on Capital Employed (2013 - 2026) Analysis & Trends
Rezolute has reported Return on Capital Employed for 14 years, with the latest figure at 70.17% in Q1 2026.
- Quarterly Return on Capital Employed rose 1289.0% year-over-year to 70.17% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 70.17% (up 1289.0% YoY) and the FY2025 annual result came in at 56.18%, up 318.0% from the prior year.
- Return on Capital Employed fell to 70.17% in Q1 2026 per RZLT's latest filing, from 64.63% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 29.26% in Q3 2022 and troughed at 83.07% in Q1 2025.
- A 5-year average of 56.21% and a median of 59.5% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed surged 4140 bps in 2022, then sank 3147 bps in 2024.
- Over 5 years, Return on Capital Employed stood at 31.79% in 2022, then plunged by 97 bps to 62.76% in 2023, then retreated by 9 bps to 68.47% in 2024, then gained by 6 bps to 64.63% in 2025, then slipped by 9 bps to 70.17% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 70.17%, 64.63%, and 52.76% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Rezolute | 442.94 Mn | 442.94 Mn | - | -70.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -70.17% |
| Dec 31, 2025 | -64.63% |
| Sep 30, 2025 | -52.76% |
| Jun 30, 2025 | -64.85% |
| Mar 31, 2025 | -83.07% |
| Dec 31, 2024 | -68.47% |
| Sep 30, 2024 | -59.50% |
| Jun 30, 2024 | -69.98% |
| Mar 31, 2024 | -69.96% |
| Dec 31, 2023 | -62.76% |
| Sep 30, 2023 | -55.49% |
| Jun 30, 2023 | -45.24% |
| Mar 31, 2023 | -38.49% |
| Dec 31, 2022 | -31.79% |
| Sep 30, 2022 | -29.26% |
| Jun 30, 2022 | -38.55% |
| Mar 31, 2022 | -50.52% |
| Dec 31, 2021 | -58.35% |
| Sep 30, 2021 | -70.66% |
| Jun 30, 2021 | -63.94% |